Walmart Inc. announced that comparable sales at its U.S. stores that have been open for at least a year rose just 2.6 percent in the second quarter of 2026, the slowest growth rate in more than six years. The figure comes from the company’s earnings release on 20 August 2026 and is confirmed by a Financial Post report that highlighted the role of pricing pressure in Walmart’s pharmacy business.
What the numbers show
According to the Financial Post, “Sales at U.S. stores open at least a year, excluding fuel, rose 2.6 per cent in the second quarter, shy of the lowest analyst estimate compiled by Bloomberg.” The same article adds that the growth rate “— hindered primarily by pricing pressure in its pharmacy business — is the slowest in more than six years.” The comparable‑sales metric excludes fuel sales and focuses on stores that have been operating for at least twelve months, providing a view of same‑store performance.
The market reaction was immediate. Walmart’s shares fell as much as 7.4 per cent shortly after the earnings were released, according to the same Financial Post excerpt.
How the quarter fits into Walmart’s broader financial picture
Walmart’s quarterly filing (Form 10‑Q) for the period ending 30 April 2026 provides a snapshot of the company’s overall financial health. The key figures are shown in the table below.
| Metric | Value | Unit | Period |
|---|---|---|---|
| Revenue | 177,751,000,000 | USD | Q2 2026 (Feb 1 – Apr 30) |
| Net income | 5,330,000,000 | USD | Q2 2026 (Feb 1 – Apr 30) |
| Total assets | 289,607,000,000 | USD | 30 April 2026 |
| Shareholders’ equity | 94,330,000,000 | USD | 30 April 2026 |
| Source: Walmart Inc. Form 10‑Q filed 29 May 2026 (SEC) | |||
Walmart’s revenue of $177.751 billion and net income of $5.33 billion illustrate the scale of the business even as comparable‑sales growth eases. The company’s total assets stand at $289.607 billion, with shareholders’ equity of $94.33 billion, according to the same filing.
Leadership and size matter for context. The SEC filing lists Doug McMillon as chief executive, the firm’s headquarters in Bentonville, Arkansas, and a workforce of roughly 2.3 million employees worldwide. These details are drawn from Walmart’s latest SEC filing (Form 8‑K filed 20 August 2026).
Why the slowdown matters for shoppers and investors
Comparable‑sales growth is a core barometer of how existing stores are performing, separate from the impact of new store openings or fuel sales. A 2.6 percent rise suggests that, on average, each store generated slightly more revenue than in the same quarter a year earlier, but the pace is markedly slower than in prior years.
The Financial Post attributes the deceleration primarily to “pricing pressure in its pharmacy business.” Pharmacy items tend to be high‑margin, and reduced pricing can suppress overall comparable‑sales growth even if other categories remain stable. The article also notes that the 2.6 percent increase fell short of the lowest analyst estimate compiled by Bloomberg, indicating that market expectations were already modest.
For investors, the immediate share‑price reaction— a drop of up to 7.4 percent— signals concern that the slowdown could reflect broader challenges in the U.S. consumer environment. While the filing does not provide forward guidance, the market’s response underscores the importance of comparable‑sales trends as a leading indicator of future earnings.
What remains unknown
Walmart has not disclosed the exact number of stores affected by the pharmacy pricing pressure, nor has it offered a detailed plan to address the issue. The earnings release and the Financial Post story do not contain any commentary on future pricing strategy, capital allocation, or expected performance for the third quarter of 2026.
Analysts will be watching the company’s next filing for any guidance on how the retailer intends to revive comparable‑sales momentum, especially in the pharmacy segment. Until then, the 2.6 percent growth figure stands as the most recent publicly available measure of same‑store performance.
In summary, Walmart’s second‑quarter 2026 results show a 2.6 percent rise in U.S. comparable sales—the weakest pace in more than six years—driven largely by pricing pressure in its pharmacy business. The slowdown coincided with a 7.4 percent dip in the stock price and adds a new data point for investors monitoring the health of the U.S. consumer market.